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OBJECTIVES We sought to evaluate: 1) the long-term outcomes of 127 selected patients receiving
unprotected left main coronary artery (LMCA) stenting; and 2) the impact of the debulking
procedure before stenting and intravascular ultrasound (IVUS) guidance on their clinical
outcomes.
BACKGROUND The long-term safety of stenting of unprotected LMCA stenoses has not been established yet.
METHODS A total of 127 consecutive patients with unprotected LMCA stenosis and normal left
ventricular function were treated by elective stenting. The long-term outcomes were evaluated
between two groups: IVUS guidance (n 5 77) vs. angiographic guidance (n 5 50); and
debulking plus stenting (debulking/stenting; n 5 40) vs. stenting only (n 5 87).
RESULTS Angiographic restenosis was documented in 19 (19%) of 100 patients. The lumen diameter
after stenting was significantly larger in IVUS-guided group (p 5 0.003). The angiographic
restenosis rate was significantly lower in the debulking/stenting group (8.3% vs. 25%, p 5
0.034). The reference artery size was the only independent predictor of angiographic
restenosis. During follow-up (25.5 6 16.7 months), there were four deaths, but no nonfatal
myocardial infarctions occurred. The survival rate was 97.0 6 1.7% at two years.
CONCLUSIONS These data suggest that stenting of unprotected LMCA stenosis might be associated with a
favorable long-term outcome in selected patients. Guidance with IVUS may optimize the
immediate results, and debulking before stenting seems to be effective in reducing the
restenosis rate. However, we need a large-scale, randomized study. (J Am Coll Cardiol 2001;
38:1054–60) © 2001 by the American College of Cardiology
Since the first report of balloon angioplasty, percutaneous
intervention has been investigated for the treatment of
unprotected left main coronary artery (LMCA) stenosis
(1–12). Unfortunately, the initial experiences of patients
undergoing unprotected LMCA interventions were dis-
couraging because of high procedural complications and
early mortality (2,9). However, recent progress in technique
and equipment, including development of newly designed
stents and use of intravascular ultrasound (IVUS) imaging,
a debulking procedure and effective antiplatelet agents, has
brought unprotected LMCA stenosis to the forefront of
interventional cardiology, making it an inviting target for
percutaneous intervention. The purposes of this study were:
1) to evaluate the long-term results of the first 127 patients
with normal left ventricular function who received unpro-
tected LMCA stenting; and 2) to evaluate the impact of the
debulking procedure before stenting and IVUS guidance on
their clinical outcomes.
METHODS
Study patients. From November 1995 to April 2000, 127
consecutive patients with unprotected LMCA stenosis and
normal left ventricular function were treated with elective
stenting at our institution. The inclusion criteria were
symptomatic LMCA disease or documented myocardial
ischemia and angiographic evidence of $50% diameter
stenosis of the LMCA. The exclusion criteria included a
contraindication to antiplatelet or anticoagulation therapy
and left ventricular dysfunction (ejection fraction ,40%).
The patients’ informed, written consent was obtained, in
accordance with the rules of the Institutional Ethics Com-
mittee, which approved the study.
Stenting procedure. The stenting procedures were de-
scribed previously and briefly as follows (11). Several stents
were used, depending on the length and location of the
lesion: 1) slotted-tube stents were primarily used for ostial
or body lesions of the LMCA; and 2) slotted-tube stents or
coil stents, or their combination, were used for distal
bifurcation lesions. For example, for an angled lesion in the
distal LMCA and proximal portion of the left circumflex
artery, a stent was placed from the LMCA into the left
circumflex artery, and then another tube stent was placed in
the proximal portion of the left anterior descending coro-
nary artery (LAD) through the struts of the stent.
The use of IVUS was the operator’s decision. Stenting
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with IVUS guidance was performed in 77 patients. The
IVUS criteria of stent optimization were as follows: 1)
complete stent-to-vessel wall apposition; 2) adequate stent
expansion (i.e., lumen cross-sectional area [CSA] of the
target lesion $90% of the distal reference lumen CSA); and
3) full lesion coverage (13).
The debulking procedure with directional atherectomy
before stenting, in 40 lesions, was generally performed
during the late study period. Optimal atherectomy and
adjunct balloon angioplasty were performed in all 40 lesions
until the residual diameter stenosis was ,10% by visual
estimation. Neither an intra-aortic balloon pump nor ab-
ciximab was used as preventive therapy. All patients, except
for the first 14 patients who took aspirin plus coumadin,
received aspirin (200 mg/day, indefinitely) and ticlopidine
(250 mg twice a day for one month) at least 48 h before
stenting.
Protocol and analysis of IVUS imaging. Pre-intervention
(n 5 56) and post-intervention (n 5 77) IVUS images were
obtained after intracoronary administration of 0.2 mg ni-
troglycerin, using a commercial IVUS system (SciMed/
Boston Scientific, San Jose, California) and motorized
pullback (at 0.5 mm/s). The external elastic membrane
(EEM), lumen and plaque plus media (5EEM-lumen)
CSAs were measured using computerized planimetry, ac-
cording to validated and published protocols (13–15). After
the intervention, the lesion site was image-sliced with the
smallest lumen CSA. The distal reference segment had the
most visually normal cross sections within 10 mm distal to
the lesion.
Quantitative coronary angiographic (QCA) analysis.
Coronary angiography was performed after intracoronary
administration of 0.2 mg nitroglycerin. The coronary an-
giographic results were analyzed by two independent an-
giographers. Using an on-line QCA system (ANCOR
version 2.0, Siemens, Solna, Sweden), the percent diameter
stenosis and minimal lumen diameter (MLD) were mea-
sured before and after the intervention and at follow-up,
from diastolic frames in single, matched view showing the
smallest lumen diameter. Angiographic restenosis was de-
fined as diameter stenosis $50% at follow-up.
Follow-up. All patients were evaluated clinically during an
office visit and/or by a telephone interview at one, two, three
and six months, and then every four months after the
intervention. Repeat coronary angiography was requested
routinely at six months, or earlier if clinically indicated.
Definitions. Procedural success was defined as ,30% re-
sidual diameter stenosis by QCA, with no major procedural
or in-hospital complications, such as death, Q-wave myo-
cardial infarction and emergency coronary artery bypass
graft surgery (CABG). A major cardiac event was defined as
the occurrence of cardiac death, nonfatal myocardial infarc-
tion or target lesion revascularization during follow-up.
Deaths were classified as either cardiac or noncardiac.
Deaths that could not be classified were considered as
cardiac-related.
Statistics. Data are expressed as the mean value 6 SD for
continuous variables and frequencies for categorical vari-
ables. Survival and event-free survival distributions were
estimated according to the Kaplan-Meier method. Logistic
regression analysis was performed on all variables to identify
the predictors of angiographic restenosis, and variables with
a p value ,0.2 by univariate analysis were entered into the
multivariate analysis. Statistical significance was defined as
p , 0.05.
RESULTS
Baseline clinical characteristics. The baseline clinical
characteristics of the patients are shown in Table 1. There
were no statistically significant differences between the two
groups. The patients’ mean age was 55.4 6 10.4 years old,
and 65% of them presented with unstable angina. Left
ventricular ejection fraction in five patients with acute
myocardial infarction was .40%. Twenty-one patients had
coronary artery disease in the right coronary artery (n 5 8)
and LAD (n 5 13)
Procedural results and in-hospital complications. Fifty-
nine lesions were located in the ostium of the LMCA, 19
lesions in the body and 49 lesions in the distal portion. The
lesion length was 4.2 6 1.5 mm for ostial lesions and 12.4 6
3.6 mm for lesions in the body and distal portions. A total
of 156 stents was deployed in 127 patients. Ninety percent
(141/156) of the stents were tubular, and the remaining 10%
(15/156) were coil-type stents. The procedural success rate
was 99.2%, and 20 patients (16%) underwent a percutane-
ous intervention in another major coronary segment. There
were no procedure-related deaths. However, one patient
had stent thrombosis (0.8%) that occurred three days after
the intervention without IVUS guidance. He was 67 years
old and had a history of diabetes mellitus, a small reference
artery size (2.3 mm) and diffuse involvement of both the
LMCA and LAD; he sustained a Q-wave acute myocardial
infarction, but was successfully treated with CABG. The
causes of stent thrombosis in this patient remain uncertain.
In the remaining patients, the in-hospital clinical outcomes
were uneventful.
Stenting with IVUS guidance. The quantitative angio-
graphic data and procedural results for the IVUS-guided vs.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CSA 5 cross-sectional area
EEM 5 external elastic membrane
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending coronary artery
LMCA 5 left main coronary artery
MLD 5 minimal lumen diameter
OR 5 odds ratio
QCA 5 quantitative coronary angiography
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angiography-guided LMCA stenting groups are presented
in Table 2. The debulking procedure before stenting was
more frequently performed in the IVUS-guided stenting
group (p 5 0.019). The treatment strategies changed from
the debulking/stenting group to the stenting-only group
because of severe calcification .90° after IVUS evaluation
in four patients. The lumen diameter after stenting was
significantly larger in the IVUS-guided group (p 5 0.003).
Pre-intervention IVUS was performed in 22 of 40 LMCA
ostial lesions. Negative remodeling (defined as EEM CSA
of the lesion site less than that of the distal reference
segment) was documented in 20 (91%) of 22 lesions.
According to IVUS criteria of stent optimization, additional
balloon angioplasty was performed in 15 (19.5%) of 77
lesions. As a consequence, the post-intervention stent CSA
increased from 10.7 6 2.8 to 13.0 6 4.0 mm2 after
additional balloon angioplasty. There was no significant
difference in the angiographic restenosis rate between the
IVUS-guided vs. angiography-guided LMCA stenting
groups.
Debulking plus stenting. The quantitative angiographic
data and procedural results for the debulking/stenting and
stenting-only groups are presented in Table 2. The IVUS
data for the two groups are shown in Table 3. Compared
with the stenting-only group, the debulking/stenting group
have a significantly lower rate of angiographic restenosis
(8.3% vs. 25.0%, p 5 0.034) and target lesion revascular-
ization (5.4% [2/37] vs. 18.8% [13/69], p 5 0.049). A
comparison of serial IVUS images before the intervention
and after directional atherectomy at the same pre-
intervention lesion site was performed in 24 of 30 lesions
with directional atherectomy plus stenting. The plaque











(n 5 87) p Value
Age (yrs) 54.7 6 9.9 56.7 6 10.9 0.289 56.1 6 9.9 55.1 6 10.6 0.606
Males 52 (68%) 35 (70%) 0.463 28 (70%) 59 (68%) 0.488
Hypertension 14 (18%) 10 (20%) 0.486 7 (18%) 17 (20%) 0.496
Diabetes mellitus 11 (14%) 9 (18%) 0.374 7 (18%) 13 (15%) 0.449
Hypercholesterolemia* 24 (31%) 14 (28%) 0.430 12 (30%) 26 (30%) 0.573
Cigarette smoking 30 (39%) 18 (36%) 0.442 15 (38%) 33 (38%) 0.562
Clinical presentation 0.557 0.849
Stable angina 27 (35%) 13 (26%) 13 (33%) 27 (31%)
Unstable angina 47 (61%) 35 (70%) 26 (65%) 56 (64%)
Acute MI 3 (4%) 2 (4%) 1 (3%) 4 (5%)
No. of diseased vessels 0.611 0.488
Two 72 (94%) 47 (94%) 37 (92%) 82 (94%)
Three 5 (6%) 3 (6%) 3 (8%) 5 (6%)
*Hypercholesterolemia . 240 mg/dl. Data are presented as the mean value 6 SD or number (%) of patients or vessels.
IVUS 5 intravascular ultrasound; MI 5 myocardial infarction.











(n 5 87) p Value
Lesion site 0.103 0.003
Os 40 (52%) 19 (38%) 11 (28%) 48 (55%)
Body 13 (17%) 6 (12%) 5 (12%) 14 (16%)
Bifurcation 24 (31%) 25 (50%) 24 (60%) 25 (29%)
Debulking before stenting 30 (39%) 10 (20%) 0.019 30 (75%) 47 (54%) 0.019
Lesion morphology 0.816 0.714
A 11 (14%) 5 (10%) 6 (15%) 10 (12%)
B1 26 (34%) 15 (30%) 11 (28%) 30 (35%)
B2 27 (35%) 20 (40%) 14 (35%) 33 (38%)
C 13 (17%) 10 (20%) 9 (22%) 14 (16%)
Reference vessel diameter (mm) 4.0 6 0.7 4.0 6 0.6 0.463 4.0 6 0.6 4.0 6 0.7 0.547
Minimal lumen diameter (mm)
Before intervention 1.2 6 0.5 1.0 6 0.5 0.020 1.1 6 0.4 1.1 6 0.5 0.896
After intervention 4.2 6 0.6 4.0 6 0.6 0.003 4.2 6 0.7 4.0 6 0.6 0.177
Follow-up 2.7 6 1.0 2.7 6 1.0 0.976 2.8 6 1.0 2.7 6 1.1 0.699
Pressure (atm) 15.1 6 2.6 15.3 6 2.8 0.327 15.0 6 3.1 15.4 6 2.5 0.284
Angiographic follow-up (%) 59/63 (94%) 41/43 (95%) 0.532 36/37 (97%) 64/69 (93%) 0.314
Angiographic restenosis rate (%) 11/59 (18.6%) 8/41 (19.5%) 0.556 3/36 (8.3%) 16/64 (25%) 0.034
Data are presented as the number (%) of lesions or the mean value 6 SD.
IVUS 5 intravascular ultrasound.
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burden decreased from 86% to 55%, and the lumen CSA
increased from 2.6 6 0.9 to 8.9 6 2.0 mm2 after directional
atherectomy. The plaque plus media CSA decreased from
19.9 6 6.5 to 12.1 6 5.6 mm2—a 30% reduction.
Predictors of angiographic restenosis. Angiographic
follow-up data were obtained for 100 of the 106 eligible
patients (follow-up rate of 94%), and restenosis ($50%
diameter stenosis) was documented in 19 (19%) of these 100
patients. Table 4 shows the univariate predictors of angio-
graphic restenosis. However, the reference artery size (odds
ratio [OR] 0.39, 95% confidence interval [CI] 0.17 to 0.87,
p 5 0.021), by angiographic analysis, was the only signifi-
cant predictor of angiographic restenosis on multivariate
analysis. The angiographic restenosis rate was statistically
different at the cut-off level of 3.6 mm for the reference
artery size: 13% (9/68) for a reference artery size .3.6 mm
vs. 31% (10/32) for #3.6 mm (p 5 0.032). The angio-
graphic restenosis rate was 13% (1/8) in the debulking/
stenting group versus 40% (8/20) in the stenting-only group
for a reference vessel size #3.5 mm (p 5 0.159), and 7%
(2/28) in the debulking/stenting group versus 18% (8/44) in
the stenting-only group for a reference vessel size .3.5 mm
(p 5 0.187). Likewise, the pre-intervention distal reference
lumen dimension (OR 0.65, 95% CI 0.44 to 0.97, p 5
0.033) was an independent predictor of angiographic resten-
osis by IVUS analysis.
Two-year clinical outcomes. All patients have completed
at least one month of clinical follow-up (mean 25.5 6 16.7
months, range 1.0 to 54.9). Four patients died during the
follow-up period (mean 12.0 6 10.7 months). One died of
an extensive myocardial infarction after elective CABG for
treatment of restenosis (at 3.5 months); one died of sepsis
(at 12.6 months); and the other two died of cancer (at 5 and
27 months). There were no nonfatal myocardial infarctions
during the follow-up period. A total of 15 patients under-
went repeat revascularization of the recurrent LMCA ste-
nosis after stenting: 9 patients had a repeat percutaneous
intervention (rotablation with balloon in 8 and rotablation
with radiation therapy in 1) and 6 patients had CABG. The
Table 3. Intravascular Ultrasound Results for Debulking Plus





Before intervention (n 5 56) n 5 24 n 5 32
Distal reference segment
Lumen MLD 3.1 6 0.8 3.1 6 0.5 0.975
Lumen CSA 9.4 6 3.5 9.7 6 3.2 0.768
EEM CSA 19.6 6 6.1 18.3 6 5.0 0.389
Lesion segment
Lumen MLD 1.7 6 0.3 1.8 6 0.3 0.375
Lumen CSA 2.8 6 1.3 2.9 6 0.9 0.674
EEM CSA 18.2 6 6.8 17.9 6 6.2 0.495
After intervention (n 5 77) n 5 30 n 5 47
Distal reference segment
Lumen MLD 3.6 6 0.5 3.4 6 0.5 0.248
Lumen CSA 11.9 6 2.9 11.0 6 3.1 0.249
EEM CSA 20.3 6 5.0 18.9 6 5.0 0.242
Lesion segment
Lumen MLD 3.7 6 0.5 3.5 6 0.5 0.159
Lumen CSA 12.9 6 2.8 12.1 6 3.4 0.231
Data are presented as the mean value 6 SD.
CSA 5 cross-sectional area; EEM 5 external elastic membrane; MLD 5
minimal lumen diameter.
Table 4. Univariate Predictors of Angiographic Restenosis
Total Restenosis
No
Restenosis OR (95% CI)
p
Value
Angiography n 5 100 n 5 19 n 5 81
Ref. MLD (mm) 4.0 6 0.7 3.7 6 0.6 4.1 6 0.7 0.39 (0.17–0.87) 0.021
Pre-intervention MLD (mm) 1.1 6 0.5 1.1 6 0.5 1.1 6 0.5 1.80 (0.63–5.18) 0.275
Final MLD (mm) 4.2 6 0.6 3.9 6 0.5 4.2 6 0.6 0.46 (0.19–1.07) 0.072
Pressure (atm) 15.2 6 2.7 15.1 6 2.4 15.3 6 2.9 0.94 (0.78–1.12) 0.480
Debulking (n) 36 3 33 0.27 (0.07–1.01) 0.052
Pre-intervention IVUS n 5 43 n 5 9 n 5 34
Distal ref. segment
Lumen MLD 3.1 6 0.6 2.7 6 0.3 3.2 6 0.6 0.11 (0.02–0.80) 0.029
Lumen CSA 9.3 6 3.3 7.0 6 1.4 9.9 6 3.5 0.66 (0.45–0.97) 0.037
EEM CSA 18.2 6 5.4 15.3 6 3.7 18.9 6 5.5 0.86 (0.73–1.02) 0.077
Lesion segment
Lumen MLD 1.7 6 0.3 1.7 6 0.2 1.7 6 0.3 0.92 (0.08–10.54) 0.949
Lumen CSA 2.9 6 1.1 2.8 6 0.7 2.9 6 1.2 0.88 (0.43–1.81) 0.724
EEM CSA 16.5 6 6.6 16.1 6 6.5 16.6 6 6.7 0.99 (0.88–1.11) 0.839
Post-intervention IVUS n 5 59 n 5 11 n 5 48
Distal ref. segment
Lumen MLD 3.5 6 0.5 3.3 6 0.5 3.5 6 0.5 0.53 (0.15–1.85) 0.319
Lumen CSA 11.1 6 2.8 10.0 6 2.7 11.4 6 2.8 0.84 (0.67–1.06) 0.138
EEM CSA 19.1 6 5.1 17.4 6 5.2 19.5 6 5.0 0.92 (0.80–1.05) 0.192
Lesion segment
Lumen MLD 3.6 6 0.5 3.4 6 0.3 3.6 6 0.5 0.41 (0.11–1.59) 0.198
Lumen CSA 12.1 6 3.0 10.8 6 1.8 12.4 6 3.2 0.82 (0.65–1.04) 0.103
Data are presented as the mean value 6 SD.
Ref. 5 reference vessel; other abbreviations as in Table 3.
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remaining four patients with asymptomatic, noncritical
restenosis were treated with medication. However, no pa-
tients required a percutaneous intervention of a nontarget
vessel during the follow-up period. Actuarial survival and
major cardiac event-free survival rates are shown in Figure
1. The survival rates were 98.1 6 1.3% and 97.0 6 1.7% at
one and two years, respectively. The cumulative probabili-
ties of major cardiac event-free survival were 86.9 6 3.3%
and 86.9 6 3.3% at one and two years, respectively, with no
late target lesion revascularization (.6 months).
DISCUSSION
The major findings of this study are: 1) stenting of unpro-
tected LMCA stenosis may be safe, with a high procedural
success rate in selected patients with normal left ventricular
function; 2) the overall long-term survival and major cardiac
event-free survival rates were good; 3) IVUS guidance may
help to achieve excellent initial outcomes; 4) the debulking
procedure before stenting appears to result in lower resten-
osis rates; and 5) the reference artery size was an indepen-
dent predictor of angiographic restenosis. These findings
may provide some new insights into the approach for
percutaneous intervention of unprotected LMCA stenosis.
Patient selection. The initial report from the Unprotected
Left Main Trunk Intervention Multicenter Assessment
(ULTIMA) registry still demonstrated relatively high sub-
acute cardiac mortality in this heterogeneous group of
patients. Many of these patients were at high risk or
ineligible for CABG, and a low left ventricular ejection
fraction was inversely related to the event rate (9,16).
Therefore, in the current study, only patients who had a left
ventricular ejection fraction $40% were included. Conse-
quently, good long-term clinical outcomes could be ex-
pected.
Guidance with IVUS. In some cases of LMCA disease, it
is often difficult to evaluate the actual size of the LMCA by
angiography (17). In particular, in cases of ostial lesions
with a certain degree of negative remodeling, the treatment
strategy should be changed from debulking with stenting to
stenting only. Therefore, IVUS before stenting provides
useful information and good procedural outcomes. The
post-stenting MLD was significantly larger in the IVUS-
guided group in this study. However, the angiographic
restenosis rate was not different between the IVUS-guided
and angiography-guided procedures (Table 2). This finding
may be partly explained by the fact that the reference vessel
size in the current study was large (4.0 mm), and the
post-stenting MLD was also large (4.0 mm), even in the
angiography-guided group. A post-stenting MLD of
4.0 mm should be large enough to maintain the final MLD,
without angiographic restenosis at follow-up.
Debulking before stenting. Aggressive debulking with
directional atherectomy before stenting may reduce the
residual plaque burden and subsequently the restenosis, as
well (18,19). The degree of debulking using directional
atherectomy in this study was comparable to that in other
reports (19–21). On univariate analysis, debulking before
stenting resulted in a significant reduction in angiographic
restenosis. However, the benefit of debulking atherectomy
was not found to be significant on multivariate analysis. In
our study, the reference vessel size of the LMCA varied
from 2.3 to 5.8 mm, and 57% of patients who had a
follow-up angiogram had large reference vessels
(.4.0 mm). The most likely explanation is that the degree
of debulking might be relatively insufficient in such large
vessels because of the limited device size. In large vessels, we
could achieve a large MLD after stent deployment by using
only high-pressure balloon dilation without debulking.
Therefore, the effect of debulking seemed to be less in these
vessels. Although there was no statistical significance, the
benefit of debulking may be more crucial in vessels that are
relatively small (,3.6 mm in this study). Regardless, it is
notable that the debulking/stenting group had a lower
restenosis rate, even though the reference diameter, final
MLD by QCA analysis and final lumen dimensions by
IVUS were similar to those in the stenting-only group. This
suggests that the plaque, itself, may contribute to the
restenosis process and supports the promise that debulking
plus stenting may reduce restenosis.
Angiographic restenosis. Although there was a trend to-
ward lower restenosis rates in the debulking group and
univariate analysis demonstrated a large post-stenting MLD
(Table 4), the reference artery size was the only independent
predictor of angiographic restenosis on multivariate analysis
in this study. In the debulking/stenting group, the angio-
graphic restenosis rate was significantly lower. However,
there were more patients with borderline diameter stenosis
(40% to 50%) at follow-up angiography in the debulking/
stenting group. Therefore, the follow-up MLD did not
achieve statistical significance in the debulking/stenting
group.
We can more clearly determine the difference in the
restenosis rate according to the reference vessel size, because
our data included various reference vessel sizes, from 2.3 to
5.8 mm. The predictor of the reference vessel size, as shown
Figure 1. Cumulative probability of survival free of cardiac death (1), total
death (2) and major cardiac events (3).
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in our study, may subsume the significance of those factors
(post-stenting MLD, minimal lumen CSA) that have been
identified previously (22–25). Based on our current analysis,
the angiographic restenosis rate was statistically higher in
the group with a reference vessel size ,3.6 mm. This cut-off
level of 3.6 mm in vessel size is an arbitrary lower threshold.
Although 31% restenosis rate in those vessels might be
slightly higher than that for non-LMCA stenting, it is still
acceptable.
Long-term clinical outcomes. In the present study, the
cumulative survival rate was 97.0 6 1.7%, and the cardiac
event-free survival rate was 86.9 6 3.3% at two years (Fig.
1); these figures are consistent with those reported in a
low-risk group of patients (12).
One-year mortality after CABG for a low-risk group
similar to that identified in this study was 5.7% (26). The
mortality rate in our series over two-year follow-up was
3.1%, which is acceptable.
For patients with restenosis, CABG was recommended
first. However, 9 (47%) of 19 patients with restenosis
received repeat angioplasty using rotational atherectomy. In
the case of a long main shaft, radiation therapy was
performed after rotational atherectomy. After a repeat
intervention, only one of them developed restenosis, 17
months after the procedure. The patient had a history of
diabetes mellitus with insulin treatment. The angiographic
findings of patients with a second episode of restenosis
showed new disease progression in the LAD and a diffuse
pattern of in-stent restenosis of the LMCA. Therefore, he
underwent elective CABG. The remaining eight patients
who had a repeat intervention were free of symptoms during
two years of follow-up.
After six months, there were no cardiac deaths or target
lesion revascularizations, indicating that the long-term clin-
ical course may be excellent after unprotected LMCA
stenting in selected patients with normal left ventricular
function. This result is consistent with previously published
data showing that the restenotic process after stenting is
time-limited and that little progression occurs beyond six
months (27,28).
Study limitations. First, our findings may not be applica-
ble to the entire range of unprotected LMCA stenoses,
because only selected patients were included. Second, this
study dealt with a relatively small number of debulking
procedures, and our results may not be conclusive for
evaluation of the role of debulking atherectomy before
stenting. Third, the risks and benefits of unprotected
LMCA stenting were not compared with those of CABG.
Conclusions. Stenting of unprotected LMCA stenosis has
no serious procedure-related complications, and overall,
long-term clinical outcomes appear to be excellent. The
IVUS-guided procedure should be used to assess unusual
lesion morphology and to optimize the immediate results,
and debulking before stenting seems to be effective in
reducing the restenosis rate. Stenting of unprotected
LMCA stenosis may be a promising alternative to CABG
in selected patient subsets with normal left ventricular
function. However, a randomized clinical trial should be
performed to validate its impact.
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